Rheumatoid Arthritis with prednisone and methotrexate

Patients with rheumatoid arthritis treated with concentrated levels of prednisone corticosteroids appear to respond well to treatment and experience minimal short-term effects on bone formation. Age, steroid-related compromise of immune function, heart failure, and diuretic use in this patient may all have contributed to the total drug toxicity. The lung infection developed due to low levels of blood cells, caused by methotrexate's toxic effects upon bone marrow. The study indicates that she was initially not diagnosed as having methotrexate pneumonia as she did not have all of the signs of the disorder.

Prednisone methotrexate rheumatoid arthritis

The median duration of prednisone treatment was significantly shorter in the methotrexate group than in the placebo group , resulting in a lower mean cumulative dose of prednisone. Moreover, fewer relapses involving cranial symptoms occurred among patients in the methotrexate group than among the control subjects. Disease relapse occurred in 9 patients in the methotrexate group, compared with 16 patients in the placebo group. All patients responded to initial treatment. One patient in the methotrexate group and 2 in the placebo group were lost to follow-up. The 2 groups were similar at baseline, with a mean age of 78 years, a mean erythrocyte sedimentation rate of 91 and 100 mm/h respectively, and a polymyalgia rheumatica prevalence of 57% and 52% respectively. Results: Twenty-one patients received prednisone and methotrexate and 21 received prednisone and placebo. Secondary outcome measures included the number of adverse effects from the treatment drugs. The primary outcome measures were the number of disease relapses and the cumulative dose of prednisone during treatment.

Methotrexate prednisone rheumatoid arthritis

Referral to a specialist in internal medicine or rheumatology can help with patient selection, assessment and subsequent follow-up. Concurrent treatment with methotrexate can reduce the duration and toxicity of prednisone corticosteroid therapy and should be considered. Practice implications: Biopsy-proven temporal arteritis should continue to be treated initially with high-dose prednisone therapy. Further studies will reveal whether a different regimen of methotrexate or another corticosteroid-sparing agent can provide similar effectiveness, with fewer side effects. Although the adverse effects associated with methotrexate in this study underline the need for due caution, the larger experience with it in the treatment of rheumatoid arthritis suggests that adverse effects can be kept to a minimum with careful patient selection, folic acid supplementation and close monitoring.